[{"id":"fe45fba3-5034-46b7-8f07-75aabce5003c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01841736","created_at":"2023-11-14T21:13:55.188Z","updated_at":"2025-02-25T16:36:15.225Z","phase":"Phase 2","brief_title":"Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors","source_id_and_acronym":"NCT01841736","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 09/20/2013","start_date":" 09/20/2013","primary_txt":" Primary completion: 03/05/2019","primary_completion_date":" 03/05/2019","study_txt":" Completion: 09/13/2025","study_completion_date":" 09/13/2025","last_update_posted":"2025-02-06"},{"id":"11c83591-4e3f-4858-aa5c-0d9de1fd1c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691465","created_at":"2023-01-20T16:00:13.319Z","updated_at":"2025-02-25T16:54:41.696Z","phase":"Phase 2","brief_title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","source_id_and_acronym":"NCT05691465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • RB1 • SYP • CHGA","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/27/2023","start_date":" 12/27/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-04"},{"id":"141adee9-39a7-4cc2-ac29-c765da1d40c0","acronym":"PLANE-PC","url":"https://clinicaltrials.gov/study/NCT04848337","created_at":"2021-09-06T20:53:42.286Z","updated_at":"2025-02-25T16:16:08.899Z","phase":"Phase 2","brief_title":"Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer","source_id_and_acronym":"NCT04848337 - PLANE-PC","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" SYP • CHGA","pipe":"","alterations":" ","tags":["SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/25/2021","start_date":" 05/25/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-14"},{"id":"bbda9792-84c4-4dce-9170-dd7e926b7ce7","acronym":"HORMONET","url":"https://clinicaltrials.gov/study/NCT03870399","created_at":"2021-01-18T19:05:05.750Z","updated_at":"2024-07-02T16:35:05.851Z","phase":"Phase 2","brief_title":"Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression","source_id_and_acronym":"NCT03870399 - HORMONET","lead_sponsor":"AC Camargo Cancer Center","biomarkers":" PGR • CHGA","pipe":"","alterations":" ","tags":["PGR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 05/13/2023","primary_completion_date":" 05/13/2023","study_txt":" Completion: 05/13/2023","study_completion_date":" 05/13/2023","last_update_posted":"2024-05-06"},{"id":"b449c2e2-ba0c-450a-b66e-b695f596786c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05988918","created_at":"2023-08-14T15:10:27.166Z","updated_at":"2024-07-02T16:35:07.542Z","phase":"Phase 2","brief_title":"Multicenter Trial of ESK981 in Patients With Select Solid Tumors","source_id_and_acronym":"NCT05988918","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" SYP • CHGA","pipe":"","alterations":" ","tags":["SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ESK981"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 04/19/2024","start_date":" 04/19/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-04-25"},{"id":"c5bedd3e-1336-4830-b58a-f2d45fad50d7","acronym":"PRRT","url":"https://clinicaltrials.gov/study/NCT04090034","created_at":"2021-01-18T20:01:02.249Z","updated_at":"2024-07-02T16:35:12.511Z","phase":"","brief_title":"Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors","source_id_and_acronym":"NCT04090034 - PRRT","lead_sponsor":"Methodist Health System","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-27"},{"id":"37ae51b7-8ad9-4388-90cd-0f703c6c8ebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03145857","created_at":"2021-01-18T15:30:16.237Z","updated_at":"2024-07-02T16:35:21.781Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use","source_id_and_acronym":"NCT03145857","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-01-30"},{"id":"abe95a5f-8246-429d-92a8-a73471011fbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01876771","created_at":"2021-01-18T08:24:57.554Z","updated_at":"2024-07-02T16:35:21.860Z","phase":"Phase 2","brief_title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","source_id_and_acronym":"NCT01876771","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 04/29/2014","start_date":" 04/29/2014","primary_txt":" Primary completion: 12/01/2033","primary_completion_date":" 12/01/2033","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2024-01-30"},{"id":"2ed109f9-55eb-4a68-a91f-9e24415e3b0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01782443","created_at":"2022-11-09T19:56:50.419Z","updated_at":"2024-07-02T16:35:40.179Z","phase":"Phase 2","brief_title":"Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors","source_id_and_acronym":"NCT01782443","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 02/13/2013","start_date":" 02/13/2013","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 12/26/2021","study_completion_date":" 12/26/2021","last_update_posted":"2023-08-14"},{"id":"da0dec94-cd85-44c3-b730-f57277d70399","acronym":"","url":"https://clinicaltrials.gov/study/NCT02743741","created_at":"2021-01-18T13:26:29.699Z","updated_at":"2024-07-02T16:35:42.111Z","phase":"","brief_title":"Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors","source_id_and_acronym":"NCT02743741","lead_sponsor":"University Health Network, Toronto","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 195","initiation":"Initiation: 07/15/2016","start_date":" 07/15/2016","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-07-25"},{"id":"86e6304f-18fe-45fe-88fc-ade5048e2472","acronym":"AIM-NETs","url":"https://clinicaltrials.gov/study/NCT04696042","created_at":"2021-01-19T20:49:35.455Z","updated_at":"2024-07-02T16:35:42.517Z","phase":"","brief_title":"Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs","source_id_and_acronym":"NCT04696042 - AIM-NETs","lead_sponsor":"Asan Medical Center","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2023-07-19"},{"id":"37969cd9-a62c-4486-b4a3-d4e0ab0714cd","acronym":"P-PRRT","url":"https://clinicaltrials.gov/study/NCT02754297","created_at":"2021-01-18T13:30:07.753Z","updated_at":"2024-07-02T16:35:46.711Z","phase":"Phase 2","brief_title":"Personalized PRRT of Neuroendocrine Tumors","source_id_and_acronym":"NCT02754297 - P-PRRT","lead_sponsor":"CHU de Quebec-Universite Laval","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 04/12/2016","start_date":" 04/12/2016","primary_txt":" Primary completion: 04/12/2025","primary_completion_date":" 04/12/2025","study_txt":" Completion: 04/12/2029","study_completion_date":" 04/12/2029","last_update_posted":"2023-06-01"},{"id":"38513ced-b11d-4c39-8c39-9b0d0b9735e1","acronym":"GETNE-T1913","url":"https://clinicaltrials.gov/study/NCT03980925","created_at":"2021-02-04T20:54:08.850Z","updated_at":"2024-07-02T16:35:54.873Z","phase":"Phase 2","brief_title":"Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.","source_id_and_acronym":"NCT03980925 - GETNE-T1913","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" IL6 • CHGA","pipe":"","alterations":" ","tags":["IL6 • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carboplatin • etoposide IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 10/11/2019","start_date":" 10/11/2019","primary_txt":" Primary completion: 02/13/2023","primary_completion_date":" 02/13/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-02-23"},{"id":"caa140a3-8acc-46aa-a82e-4cf4a0599384","acronym":"","url":"https://clinicaltrials.gov/study/NCT00843037","created_at":"2021-01-18T03:12:32.905Z","updated_at":"2024-07-02T16:35:56.937Z","phase":"Phase 2","brief_title":"Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma","source_id_and_acronym":"NCT00843037","lead_sponsor":"University Health Network, Toronto","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 03/14/2022","primary_completion_date":" 03/14/2022","study_txt":" Completion: 03/14/2022","study_completion_date":" 03/14/2022","last_update_posted":"2023-01-26"},{"id":"34bbec34-4daa-4d0a-80bd-efb11de7e324","acronym":"PALACE","url":"https://clinicaltrials.gov/study/NCT04852679","created_at":"2021-04-21T11:53:31.620Z","updated_at":"2024-07-02T16:35:57.483Z","phase":"Phase 3","brief_title":"Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs","source_id_and_acronym":"NCT04852679 - PALACE","lead_sponsor":"Ipsen","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 06/10/2022","primary_completion_date":" 06/10/2022","study_txt":" Completion: 01/13/2023","study_completion_date":" 01/13/2023","last_update_posted":"2023-01-18"},{"id":"0c90cd30-d9b5-4626-af27-72cee25782de","acronym":"REBORN","url":"https://clinicaltrials.gov/study/NCT04464122","created_at":"2021-01-18T21:27:30.836Z","updated_at":"2024-07-02T16:36:00.020Z","phase":"","brief_title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","source_id_and_acronym":"NCT04464122 - REBORN","lead_sponsor":"University of Roma La Sapienza","biomarkers":" KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3","pipe":"","alterations":" ","tags":["KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 09/14/2024","primary_completion_date":" 09/14/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-11-23"},{"id":"9bfec321-b7bc-47c7-9fb1-8bf0511e4140","acronym":"","url":"https://clinicaltrials.gov/study/NCT01842165","created_at":"2021-01-18T08:12:35.783Z","updated_at":"2024-07-02T16:36:00.646Z","phase":"Phase 3","brief_title":"177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs","source_id_and_acronym":"NCT01842165","lead_sponsor":"Jules Bordet Institute","biomarkers":" SSTR • CHGA","pipe":"","alterations":" ","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 09/19/2022","study_completion_date":" 09/19/2022","last_update_posted":"2022-11-10"},{"id":"ec1adf57-4b93-40ed-a520-5818d6ccc8e0","acronym":"ELECT","url":"https://clinicaltrials.gov/study/NCT00774930","created_at":"2021-01-18T02:55:41.727Z","updated_at":"2024-07-02T16:36:02.435Z","phase":"Phase 3","brief_title":"An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome","source_id_and_acronym":"NCT00774930 - ELECT","lead_sponsor":"Ipsen","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2022-10-14"},{"id":"058d1321-7be9-48a4-947c-65800088332e","acronym":"CLARINET","url":"https://clinicaltrials.gov/study/NCT00353496","created_at":"2021-01-18T01:13:26.014Z","updated_at":"2024-07-02T16:36:02.649Z","phase":"Phase 3","brief_title":"Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours","source_id_and_acronym":"NCT00353496 - CLARINET","lead_sponsor":"Ipsen","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 264","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2022-10-11"},{"id":"94b6dead-a63b-42b0-93fd-a6f6cb3ccf4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04123262","created_at":"2021-01-18T20:08:31.135Z","updated_at":"2024-07-02T16:36:02.882Z","phase":"Phase 2","brief_title":"Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression","source_id_and_acronym":"NCT04123262","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PGR • CHGA","pipe":"","alterations":" ","tags":["PGR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-10-07"},{"id":"d8d92c20-f9b0-4b65-887c-9b325e1515f6","acronym":"LAMPARA","url":"https://clinicaltrials.gov/study/NCT03946527","created_at":"2021-01-18T19:25:49.115Z","updated_at":"2024-07-02T16:36:02.836Z","phase":"Phase 2","brief_title":"LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)","source_id_and_acronym":"NCT03946527 - LAMPARA","lead_sponsor":"Antonio Fojo","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/17/2019","start_date":" 06/17/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-10-07"},{"id":"1c7411aa-3958-4e55-a6f9-57809423a865","acronym":"CLARINET FORTE","url":"https://clinicaltrials.gov/study/NCT02651987","created_at":"2021-01-18T12:54:41.991Z","updated_at":"2024-07-02T16:36:03.082Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg","source_id_and_acronym":"NCT02651987 - CLARINET FORTE","lead_sponsor":"Ipsen","biomarkers":" SSTR • GAST • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • GAST • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 10/16/2019","primary_completion_date":" 10/16/2019","study_txt":" Completion: 10/24/2019","study_completion_date":" 10/24/2019","last_update_posted":"2022-10-03"},{"id":"19b1a970-d50a-42b1-b90b-f30023410f69","acronym":"","url":"https://clinicaltrials.gov/study/NCT02695459","created_at":"2021-01-18T13:09:29.829Z","updated_at":"2024-07-02T16:36:31.463Z","phase":"Phase 2","brief_title":"Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin","source_id_and_acronym":"NCT02695459","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/30/2016","start_date":" 03/30/2016","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-04-20"},{"id":"a6d2ab39-a519-4fdb-aca6-2f51916bba32","acronym":"","url":"https://clinicaltrials.gov/study/NCT01468532","created_at":"2021-01-18T06:06:48.742Z","updated_at":"2024-07-02T16:36:32.814Z","phase":"Phase 1/2","brief_title":"Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT01468532","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" IGF1 • CHGA","pipe":"","alterations":" ","tags":["IGF1 • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • Signifor (pasireotide) • Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 07/20/2017","primary_completion_date":" 07/20/2017","study_txt":" Completion: 07/20/2017","study_completion_date":" 07/20/2017","last_update_posted":"2021-03-25"}]